About Dr. Reddy's Laboratories Ltd Common Stock (RDY)
Dr. Reddy's Laboratories is a global pharmaceutical company based in India that focuses on the development, manufacturing, and marketing of a wide range of healthcare products. The company specializes in generic medications, active pharmaceutical ingredients, and proprietary formulations, catering to various therapeutic areas such as oncology, cardiovascular, and pain management. Dr. Reddy's is committed to improving access to quality medicine for patients around the world and engages in research and development to innovate and advance healthcare solutions. Through its extensive portfolio, the company contributes to both the pharmaceutical market and public health initiatives. Read More
Dr. Reddy's Laboratories (NYSE:RDY) said a scale-up issue tied to the active pharmaceutical ingredient for its semaglutide injection will temporarily delay commercial supplies, though management emphasized that products already supplied to the market are not affected and do not raise patient safety
Dr Reddy's Laboratories (NYSE:RDY) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call
Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for the development and manufacturing of the product.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical company, today announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy’s is among the first companies to introduce a generic Semaglutide Injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28th, 2026. Canada is the first G7 country to grant market authorization for Semaglutide Injection. The launch demonstrates Dr. Reddy’s readiness to ensure patient access following approval.
Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter.
Narasimham said the company’s und
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), a global pharmaceutical company, today announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection. Dr. Reddy’s becomes the first company to receive the market authorization for generic Semaglutide Injection* in Canada, ahead of Health Canada’s review target date. The market authorization covers the 2 mg / pen (1.34 mg / mL) and 4 mg / pen (1.34 mg / mL). With launch preparations underway, Dr. Reddy’s is well-positioned to bring this important treatment option available to Canadian patients.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced that the US Food and Drug Administration (USFDA) has accepted for review, its 351 (k) Biologics License Application (BLA) IV for infusion formulation for DRL_AB, a proposed interchangeable biosimilar to ORENCIA® (abatacept) that was submitted in December 2025.
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra Strength Pataday® Once-Daily Relief, in the U.S. market, as approved by the U.S. Food and Drug Administration (USFDA).
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL).
Dr. Reddy's Labs fits the Peter Lynch investment model with strong EPS growth, a low PEG ratio, minimal debt, and high ROE, making it a compelling GARP stock.
Dr. Reddy's Laboratories aligns with Peter Lynch's GARP strategy, showing strong financial health, steady earnings growth, and an attractive valuation with a low PEG ratio.
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein Degradation (TPD) and Proximity Inducer Platform (A-PROX) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held at the Hynes Convention Center in Boston, MA, from October 22–26, 2025.
Dr. Reddy's Laboratories (RDY) exemplifies Peter Lynch's GARP strategy with strong 23.6% EPS growth, a low 0.80 PEG ratio, and excellent financial health.
Discover how Dr. Reddy's Laboratories (RDY) exemplifies Peter Lynch's GARP investing strategy with strong earnings growth, a low PEG ratio, and a robust financial profile.
Dr. Reddy's Labs (RDY) fits Peter Lynch's GARP strategy with steady earnings growth, strong profitability, low debt, and fair valuation—ideal for long-term investors.
